Role of Bisphosphonates for the Management of Skeletal Complications and Bone Pain from Skeletal Metastases

Costa, Luís; Lipton, Allan; Coleman, Robert E.

doi:10.3816/sct.2006.n.012

Cited by 25 publications

(19 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The treatment of bone metastases with bisphosphonates has meant a great improvement in these patient's functional prognosis for a significant reduction of complications has been demonstrated after 6 months of treatment. 13,14 New therapeutic targets in these patients are the molecules that regulate osteoclasts maturation and differentiation. 5,15 Patients with bone metastases can also benefit from radiotherapy, which has shown good analgesic effect and a decrease of osteolytic activity.…”

Section: Discussionmentioning

confidence: 99%

Pathological Vertebral Compression Fracture of C3 Due to a Breast Cancer Metastasis in a Male Patient

López-O’Rourke¹,

Orient-López²,

Fontg-Manzano³

et al. 2009

Spine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Pathological Vertebral Compression Fracture of C3 Due to a Breast Cancer Metastasis in a Male Patient

López-O’Rourke¹,

Orient-López²,

Fontg-Manzano³

et al. 2009

Spine

View full text Add to dashboard Cite

show abstract

“…Some animal experiments have observed ZA antitumour activity outside the bone (soft tissue tumours or visceral metastasis), but they have exceeded the total cumulative dose recommended in clinical practice and the doses used in these studies ranged from 80 µg/kg on three sequential days a week for two weeks to 100 µg/kg daily for 6 [71]. ZA is a useful supporting treatment for patients with MBD and has become incorporated into the care of patients with bone involvement from solid tumours and multiple myeloma to decreases the risk of SREs [72,73].…”

Section: Antitumour Effects Of Zamentioning

confidence: 99%

Direct antitumour activity of zoledronic acid: preclinical and clinical data

et al. 2011

View full text Add to dashboard Cite

Bisphosphonates (BPs) are widely used in the management of metastatic bone disease to reduce skeletal morbidity. Zoledronic acid (ZA), the most potent BP in clinical use, has demonstrated clinical utility in multiple tumour types. Preclinical data indicate that ZA may have direct antitumour activity, as has been demonstrated preclinically in both in vitro and in vivo experiments. The majority of preclinical studies showing antitumour effects have used high doses of ZA, making it difficult to translate these data to the clinical setting. This review summarises the published data on antitumour effects of ZA in tumour cell lines, mice experiments, and human clinical trials. Translational questions regarding drug dose, dose interval, and sequence with chemotherapy treatment are also addressed.

show abstract

“…However, practical guidelines for the prevention, diagnosis and management of ONJ have recently been published [29,30,31]. …”

Section: Discussionmentioning

confidence: 99%

Bisphosphonate-Associated Osteonecrosis of the Jaw in Patients with Multiple Myeloma and Breast Cancer

Nastro

Musolino²,

Allegra³

et al. 2006

Acta Haematol

View full text Add to dashboard Cite

Osteonecrosis of the jaw is an unremitting adverse outcome associated with bisphosphonate therapy in patients with multiple myeloma or bone metastases from solid tumors. Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure. The discontinuation of bisphosphonate therapy has not helped reverse the presence of osteonecrosis, and the surgical manipulation of the involved site appears to worsen the underlying bone pathology. Hyperbaric oxygen, which has proven efficacious in other forms of osteonecrosis by establishing an oxygen gradient, is of no definitive benefit to patients with bisphosphonate-induced exposed bone. Antibiotic therapy is useful in controlling pain and swelling but ineffective in preventing the progression of the exposed bone. To date, prevention is the only currently possible therapeutic approach to the management of this complication.

show abstract

Role of Bisphosphonates for the Management of Skeletal Complications and Bone Pain from Skeletal Metastases

Cited by 25 publications

References 77 publications

Pathological Vertebral Compression Fracture of C3 Due to a Breast Cancer Metastasis in a Male Patient

Pathological Vertebral Compression Fracture of C3 Due to a Breast Cancer Metastasis in a Male Patient

Direct antitumour activity of zoledronic acid: preclinical and clinical data

Bisphosphonate-Associated Osteonecrosis of the Jaw in Patients with Multiple Myeloma and Breast Cancer

Contact Info

Product

Resources

About